Cetera Investment Advisers Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Cetera Investment Advisers lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,021,564 shares of the biopharmaceutical company's stock after selling 40,924 shares during the period. Cetera Investment Advisers' holdings in Pfizer were worth $53,632,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter worth $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 4.0 %

Shares of NYSE:PFE opened at $22.92 on Wednesday. The business has a 50 day moving average of $24.22 and a two-hundred day moving average of $25.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market capitalization of $129.97 billion, a PE ratio of 16.25, a PEG ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.51%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.